venus remedies will hold its 37th Annual General Meeting on August 20, 2026, at 11:30 A.M. via Video Conferencing/Other Audio-Visual Means to approve a final dividend of ₹10 per equity share and finalize key board appointments for the financial year ended March 31, 2026. The meeting represents a significant governance milestone, consolidating leadership transitions while rewarding shareholders with the first dividend payout in over a decade, reflecting the company’s strengthened financial position.

The Board of Directors recommends the declaration of a final dividend of ₹10 per equity share, equivalent to 100% on the face value of ₹10. This payout marks the resumption of dividend distribution after more than ten years, signaling management’s confidence in sustainable earnings potential and cash generation capabilities. The dividend is payable to members whose names appear in the Register of Members on the record date of August 7, 2026.

Board Appointments and Re-appointments

The AGM agenda includes several critical personnel resolutions under the Companies Act, 2013. Shareholders are asked to approve the appointment of Saransh Chaudhary as Executive Director (Whole-Time Director) for a five-year term commencing from May 26, 2026. Chaudhary, who currently serves as CEO of Venus Medicine Research Centre, receives an annual salary of ₹93.00 Lacs including bonus and perquisites.

Additionally, the meeting seeks approval for the re-appointment of Dr. (Mrs.) Manu Chaudhary as Joint Managing Director for five years, effective October 1, 2026, with an annual remuneration of ₹153.50 Lacs. Dr. (Mrs.) Savita Gupta is also up for re-appointment as an Independent Non-Executive Director for a second consecutive term ending December 28, 2031.

Statutory and Governance Resolutions

The ordinary business includes the adoption of audited standalone and consolidated financial statements for FY26. Under special business, shareholders must ratify the remuneration of M/s C. L. Bansal & Associates as Cost Auditors for FY26-27, fixed at ₹1,10,000 plus applicable taxes and out-of-pocket expenses. This ratification is mandated under Section 148 of the Companies Act, 2013.

Furthermore, the agenda includes a special resolution to alter the Memorandum of Association (MOA) and adopt new Articles of Association (AOA). These changes align the company’s constitutional documents with the Companies Act, 2013, SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, and prevailing corporate governance practices. The MOA amendment clarifies main objects versus ancillary objects and updates liability clauses.

Voting and Participation Details

Remote e-voting will be available from August 17, 2026, at 9:00 A.M. IST until August 19, 2026, at 5:00 P.M. IST. The cut-off date for determining voting eligibility is August 13, 2026. Members holding shares on this date may join the virtual meeting via InstaMeet facility. Proxy appointments are not available for this VC/OAVM meeting. The scrutinizer for the e-voting process is Mr. Prince Chadha of M/s P. Chadha & Associates.

Venus Remedies reported a consolidated net profit of ₹22.97 crore for the quarter ended June 30, 2026, representing a 118% increase from ₹9.60 crore in the corresponding period of the previous year. Revenue from operations grew to ₹178.86 crore from ₹137.18 crore in Q1FY25. The company's board approved the unaudited financial results for the quarter during a meeting held on July 20, 2026.

The standalone financial results showed a net profit of ₹25.53 crore, compared to ₹11.70 crore in the same quarter last year. Standalone revenue from operations was reported at ₹178.80 crore. The results were reviewed by the Audit Committee and the statutory auditors, J. K. Jain & Associates, provided a limited review report pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance

The company's earnings per share (EPS) on a consolidated basis for the quarter was ₹17.18, up from ₹7.18 in the previous year. EBITDA for the quarter stood at ₹36.81 crore compared to ₹18.80 crore in Q1FY25, with the EBITDA margin expanding to 19.10% from 7.66% in the year-ago period. Total comprehensive income for the period stood at ₹28.88 crore. The board noted that the group has only one reportable segment, Pharmaceuticals.

The following table summarises the key consolidated financial metrics for the quarter:

Corporate Governance Updates

The board approved revisions to the proposed alteration of the Memorandum of Association (MOA). These changes are intended to align the Object Clause with the provisions of the Companies Act, 2013 and update the main objects to reflect current business practices. The principal business activities remain unchanged, and the company continues to operate in the pharmaceutical sector. The revised MOA will be placed before shareholders for approval via a Special Resolution at the ensuing 37th Annual General Meeting.

Subsidiary and Auditor Observations

The independent auditor's report highlighted an emphasis of matter regarding outstanding share application money amounting to ₹2,859.72 lakhs in respect of Venus Pharma GmbH, a wholly owned subsidiary. The share allotment is pending as it is not mandatory under German laws. Management stated the investment is strategic and intends to recover the amount following the restructuring of European operations in FY 2026-27. The auditor also noted that Venus Pharma GmbH reported a net loss of ₹2.55 crore for the quarter, while its step-down subsidiary, Venus Pharma Kft, reported nil revenue and profit.